Back to News

Life Sciences Companies Adopt ³Ô¹Ï±¬ÁÏ Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance

Next-generation commercial data warehouse speeds implementation and automatically syncs with most important data sources

PLEASANTON, CA ¡ª March 19, 2019 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE:VEEV) today announced that life sciences companies are adopting ³Ô¹Ï±¬ÁÏ Nitro to accelerate their data warehouse projects and deliver faster insights to the business. ³Ô¹Ï±¬ÁÏ Nitro is a life sciences-specific commercial data warehouse that eliminates the time and effort of custom data warehouses and provides a foundation for artificial intelligence (AI) and advanced analytics. In half a year since the product¡¯s availability, six companies have selected ³Ô¹Ï±¬ÁÏ Nitro, including Karyopharm Therapeutics (NASDAQ:KPTI) and MannKind Corporation (NASDAQ:MNKD), with both customers live and using the product in under five months.

With a fast-growing oncology business and a new therapy coming to market, Karyopharm Therapeutics needed to bring together a variety of data sets ¨C including ³Ô¹Ï±¬ÁÏ CRM and claims data ¨C to empower field teams with the right information to reach the right stakeholders.

¡°³Ô¹Ï±¬ÁÏ Nitro removed many of the challenges in implementing a data warehouse and accelerated our ability to provide the field with useful, actionable insights,¡± said Jason Magyar, sr. director, enterprise applications, Karyopharm Therapeutics. ¡°In just a few months, we gained a host of capabilities with ³Ô¹Ï±¬ÁÏ Commercial Cloud and ³Ô¹Ï±¬ÁÏ Nitro that other solutions sometimes take years to deliver, if ever. We now have a solid foundation for growth and to drive intelligent customer engagement.¡±

³Ô¹Ï±¬ÁÏ Nitro provides an industry-specific data model and standard integrations that unify a company¡¯s most important data sources, including prescription, sales, formulary, and claims data. Data is automatically updated when data structures or sources change, eliminating the significant effort typically required to maintain a custom-built data warehouse.

Analytics-ready, ³Ô¹Ï±¬ÁÏ Nitro also gives companies the flexibility to use the business intelligence and AI tools of their choice. With seamless integration to ³Ô¹Ï±¬ÁÏ CRM MyInsights, any time data changes in ³Ô¹Ï±¬ÁÏ Nitro it automatically syncs in ³Ô¹Ï±¬ÁÏ CRM MyInsights. Now customers can deliver tailored insights to field teams right at the point of execution on any mobile device.

¡°³Ô¹Ï±¬ÁÏ Nitro allowed us to build and configure our data warehouse quickly and efficiently,¡± said Andrew Zepfel, associate director, sales operations, MannKind Corporation, a biopharmaceutical company that provides therapeutic products for patients with diseases such as diabetes. ¡°³Ô¹Ï±¬ÁÏ Nitro will allow us to keep up with changes in the business as they happen and give us a foundation for advanced analytics.¡±

¡°For decades the life sciences industry has been held back by custom data warehouses that are inflexible and out-of-date, so they fail to deliver the right insights to the business,¡± said Andy Fuchs, vice president, ³Ô¹Ï±¬ÁÏ Nitro. ¡°³Ô¹Ï±¬ÁÏ Nitro finally gives companies a pre-built commercial data warehouse that is fast to deploy and delivers always current insights at speeds that were never before possible.¡±

³Ô¹Ï±¬ÁÏ Nitro is available today in North America and Japan and planned for availability in Europe in mid-2019.

Learn more about ³Ô¹Ï±¬ÁÏ Nitro at the upcoming ³Ô¹Ï±¬ÁÏ Commercial & Medical Summit, May 13-15 in
Philadelphia, PA. The event is open to ³Ô¹Ï±¬ÁÏ customers and invited guests. Register and view the
agenda at veeva.com/Summit.

Additional Information
For more on ³Ô¹Ï±¬ÁÏ Nitro, visit: veeva.com/Nitro
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
Follow @veevasystems on Twitter:
Like ³Ô¹Ï±¬ÁÏ on Facebook:

About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ has more than 700 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. ³Ô¹Ï±¬ÁÏ is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ¡¯s products and services, the results from use of ³Ô¹Ï±¬ÁÏ¡¯s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ¡¯s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ¡¯s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ¡¯s financial results are included under the captions, ¡°Risk Factors¡± and ¡°Management¡¯s Discussion and Analysis of Financial Condition and Results of Operations,¡± in the company¡¯s filing on Form 10-Q for the period ended October 31, 2018. This is available on the company¡¯s website at veeva.com under the Investors section and on the SEC¡¯s website at . Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.

###

Contact:

³Ô¹Ï±¬ÁÏ Systems
925-264-8885

Jeremy Whittaker
³Ô¹Ï±¬ÁÏ Systems
+49 6950955486
jeremy.whittaker@veeva.com